About the ETPNThe European Technology Platform on Nanomedicine
What is the ETPN?
The ETP Nanomedicine (ETPN) is an initiative led by industry since 2005 and set up together with the European Commission, to address the application of nanotechnology in healthcare. The ETPN believes that involving industry will accelerate the development of promising ideas, and provide the effective and safe healthcare products that patients demand.
The ETPN is officially recognized as an ETP, a key element in the European innovation ecosystem and a main bridge between the community and the European Commission to implement Research FrameWork Programmes.
In 2015, the ETPN became an independent Association under the French law 1901, with its Secretariat in central Paris, in the campus of the ESPCI (Ecole Supérieure de Physique et Chimie Industrielle de la ville de Paris). The association gathers today more than 125 members from 25 different Member States, covering all stakeholders of Nanomedicine : academia, SMEs, industry, pubic agencies, representatives from national platforms, European Commission, etc.
The strategic research priorities of the ETP Nanomedicine represent the core fields of interest and activities of the members of the technology platform: Regenerative Medicine and Biomaterials, Nanotherapeutics( including drug delivery), Medical devices including Nanodiagnostics and Imaging.
The ETPN acts as:
The Think Tank of Nanomedicine in Europe
Supporting public funding of the most promising R&D topics – “where Nanomedicine can bring something more” – through strategic inputs coming for all stakeholders, towards the E.C.
A driving force for industrialization
Detecting the best innovations in Nanomedicine and facilitate their access to the clinic through the Nanomedicine Translation Hub, a global set of premium services, free-of-charge for the beneficiaries.
The ETPN drives the emergence of Nanomedicine with HealthTech
Since October 2017, The ETPN coordinates the NOBEL Project which builds a unique ecosystem in EUROPE for the convergence of Nanomedicine & emerging medical technologies. NOBEL is a Coordination and Support Action (C.S.A.) funded for three years by the European Union’s Horizon 2020 research and innovation programme (grant agreement no .766492).
From precision engineering to smart connected Healthtech, NOBEL is paving the way for the new ESTHER Healthtech value chain, supporting translation of innovative concepts into healthcare solutions. ESTHER is the next big think in Medical Technologies in Europe! Its vision is transforming patient outcome and healthcare sustainability by providing innovative
Become a new member of ETPN!
and benefit notably from free registration at NME19!